Dr. Mizrahi on the Goal of the COMMIT Trial in dMMR Metastatic CRC

In Partnership With:

Partner | Cancer Centers | <b>The University of Texas MD Anderson Cancer Center</b>

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Jonathan Mizrahi, MD, fellow at The University of Texas MD Anderson Cancer Center, discusses the goal of the phase III COMMIT trial (NCT02997228) in mismatch repair deficient (dMMR) colorectal cancer (CRC).

The ongoing COMMIT trial is evaluating the effectiveness of combination chemotherapy, bevacizumab (Avastin) and/or atezolizumab (Tecentriq) in the treatment of patients with dMMR metastatic CRC. Patients with be randomized 1:1:1 to 3 arms: mFOLFOX6 plus bevacizumab, atezolizumab monotherapy, or mFOLFOX6 plus atezolizumab and bevacizumab, explains Mizrahi.

The goal of the COMMIT trial is to see whether chemotherapy can be omitted altogether for this patient population or whether the addition of immunotherapy to chemotherapy will improve outcomes. Results from this study should provide clarity for how best to treat this patient population, concludes Mizrahi.